Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) announced participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Management will present during a fireside chat on February 15, 2022, at 4:30 PM EST. The conference aims to enhance patient outcomes through personalized diagnostic insights. Notably, Oncocyte offers proprietary tests like DetermaRx™ and DetermaIO™ to assist in cancer diagnosis and treatment. Investors can reach out to BTIG representatives for meeting opportunities, though the presentation won't be webcast.

IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that management will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Presentation Details:

BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Fireside Chat: Tuesday, February 15, 2022
Time: 4:30PM EST

Investors interested in meeting with the Oncocyte management team during these events should contact their respective BTIG representatives. This presentation will not be webcast due to the format of the conference.

About Oncocyte
Oncocyte is a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™, a gene expression test currently used as a research-use only tool, assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, blood-based monitoring test DetermaCNI™, and long-term recurrence monitoring test DetermaMx™. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and TheraSure™ are trademarks of Oncocyte Corporation.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

Media Contact
Megan Kernan
ICR Westwicke Healthcare PR
Tel: 646.677.1870
Megan.kernan@westwicke.com

FAQ

When will Oncocyte present at the BTIG MedTech Conference?

Oncocyte will present during a fireside chat on February 15, 2022, at 4:30 PM EST.

What is the focus of Oncocyte Corporation?

Oncocyte focuses on precision diagnostics to improve patient outcomes in cancer care.

What is DetermaRx™, and how does it relate to Oncocyte?

DetermaRx™ is a test developed by Oncocyte to identify early-stage lung cancer patients at high risk for recurrence.

Is the presentation by Oncocyte at the conference available online?

No, the presentation will not be webcast due to the conference format.

Which products does Oncocyte offer for cancer diagnostics?

Oncocyte offers several tests including DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, and DetermaMx™.